Boston Scientific Corp (BSX)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 1,853,000 | 1,593,000 | 698,000 | 1,041,000 | -140,000 |
| Total stockholders’ equity | US$ in thousands | 21,770,000 | 19,282,000 | 17,574,000 | 16,623,000 | 15,327,000 |
| ROE | 8.51% | 8.26% | 3.97% | 6.26% | -0.91% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $1,853,000K ÷ $21,770,000K
= 8.51%
Based on the data provided, Boston Scientific Corp's return on equity (ROE) has shown variations over the past five years. In 2020, the company had a negative ROE of -0.91%, indicating a loss in shareholder value relative to the equity invested.
However, there has been an improvement in ROE in the following years. By the end of 2021, the ROE increased to 6.26%, suggesting a modest recovery in profitability and efficiency in generating returns for shareholders.
In 2022 and 2023, the ROE values remained stable at 3.97% and 8.26% respectively, indicating a consistent performance in utilizing equity to generate profits.
The most recent data point for 2024 shows a further increase in ROE to 8.51%, reflecting an improvement in the company's ability to generate returns on shareholder equity.
Overall, the trend in Boston Scientific Corp's ROE indicates a mix of challenges and improvements over the years, highlighting the importance of monitoring and analyzing this metric to assess the company's financial performance and efficiency in utilizing shareholder funds.
Peer comparison
Dec 31, 2024